Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years.

Next Previous
Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Monovalent Pandemic H5N1 Vaccine 1557484A in Adults Aged 18 - 64 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2016

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 21 Dec 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 21 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 21 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top